18 completed, 6 terminated, 2 active not recruiting, 1 recruiting. 21 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 15, Terminated 4, Active not recruiting 1, Unknown 1 |
| Phase 2 | 16 | Completed 8, Terminated 4, Active not recruiting 2, Recruiting 1, Unknown 1 |
Follow Array BioPharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma Binimetinib, Imatinib - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | University of California, San Francisco | 25 | 2021-03-03 | 2026-08-18 |
| Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Binimetinib, Nivolumab, Questionnaire Administration - Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8 | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 3 | 2020-12-03 | 2024-12-04 |
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab - Renal Cell Carcinoma, Melanoma | Phase 1 / Phase 2 | Active not recruiting | Dan Zandberg | 70 | 2020-06-11 | 2025-11-06 |
| Lorlatinib Combinations in Lung Cancer Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1 / Phase 2 | Unknown | Massachusetts General Hospital | 96 | 2020-05-01 | 2021-03-10 |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer Binimetinib, Brigatinib - ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma | Phase 1 | Terminated | University of California, San Francisco | 3 | 2020-02-25 | 2022-10-17 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers Binimetinib, Encorafenib - Advanced BRAF Mutant Cancers | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2019-02-14 | 2024-10-21 |
| Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) Pembrolizumab, Binimetinib, Oxaliplatin - Metastatic Colorectal Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 116 | 2018-02-16 | 2024-11-21 |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Binimetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 2 | Completed | University of Alabama at Birmingham | 45 | 2017-11-28 | 2025-05-02 |
| Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Binimetinib, Palbociclib - Lung Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 34 | 2017-05-31 | 2026-02-12 |
| A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) MEK162, Pexidartinib - Gastrointestinal Stromal Tumor (GIST) | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2017-04-15 | 2021-04-30 |
| BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) Encorafenib, Binimetinib - Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation | Phase 2 | Completed | University of Heidelberg Medical Center | 12 | 2016-06-01 | 2023-11-24 |
| Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients Filanesib, pomalidomide and dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | PETHEMA Foundation | 47 | 2015-09-01 | 2022-07-27 |
| An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) MEK-162, Nilotinib, Questionnaires - Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2015-03-11 | 2020-02-12 |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations WNT974, LGX818, Cetuximab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2014-12-01 | 2017-10-09 |
| MEK and MET Inhibition in Colorectal Cancer PF-02341066, PD-0325901, Binimetinib - Solid Tumor, Colorectal Cancer | Phase 1 | Completed | University of Oxford | 82 | 2014-11-01 | 2021-07-13 |
| MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy MEK 162 - Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2014-08-27 | 2021-04-20 |
| MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer MEK inhibitor MEK162, leucovorin calcium, fluorouracil - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | City of Hope Medical Center | 26 | 2014-07-16 | 2026-10-19 |
| A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation MEK162, Erlotinib - Lung Cancer, Non-Small Cell Lung Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 43 | 2013-12-30 | 2023-01-19 |
| LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma LGX818 - Melanoma | Phase 2 | Terminated | Array BioPharma | 15 | 2013-11-01 | 2017-01-09 |
Showing 20 of 28. Sign in to see all of them.
Melanoma (6) · Lung Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Recurrence (3) · Breast Neoplasms (2) · Leukemia (2) · Multiple Myeloma (2) · Blast Crisis (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Diabetes Mellitus, Type 2 (1) · Disease Progression (1) · Gastrointestinal Stromal Tumors (1) · Leukemia, Myeloid, Acute (1)
binimetinib (17) · encorafenib (6) · Crizotinib (2) · Fluorouracil (2) · Gemcitabine (2) · Leucovorin (2) · Nivolumab (2) · Oxaliplatin (2) · ARRY-334543 (1) · ARRY-403 (1) · Alpelisib (1) · Cetuximab (1) · Cisplatin (1) · Dexamethasone (1) · ErbB Receptors (1)
United States (25) · Canada (5) · Australia (4) · Spain (4) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Switzerland (2) · United Kingdom (2) · Belgium (1) · Israel (1) · Singapore (1)
Bruce Korf, MD, PhD (1) · Collin Blakely, MD, PhD (1) · Dan Zandberg, MD (1) · Farhad Ravandi-Kashani, MD (1) · Geoffrey Shapiro, MD, PhD (1) · Ghassan Abou-Alfa, MD (1) · Ibiayi Dagogo-Jack, MD (1) · Jhanelle Gray, M.D. (1) · Katy Tsai, MD (1) · Laura Huppert, MD (1) · Marc S. Raab, PD Dr. med. (1) · Mark R Middleton (1) · Marwan Fakih (1)
PMID 10564685, PMID 15902208, PMID 15958804, PMID 17975015, PMID 18032762, PMID 18032763, PMID 19901123, PMID 31213500, PMID 32461105, PMID 32501528, PMID 35385748, PMID 36608320, PMID 36811382, PMID 37499521, PMID 38653648, PMID 38762348, PMID 40578933, PMID 8797771
2014 (1)